BD unveils diagnostic informatics and automation innovations at ECCMID
Medical technology company, Becton, Dickinson and Company (BD), has introduced several new informatics and automation solutions for clinical laboratories.
The company announced the new molecular, microbiology and software solutions at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Announced at the congress was Synapsys microbiology informatics solution, software which provides laboratories with secure connectivity across instruments and locations. The browser-based application helps streamline workflows, automate manual processes, and facilitate on-demand actionable insights.
The software will initially support select BD products with plans to include other BD clinical microbiology instruments in the future.
The solution is designed to help laboratories and hospitals meet cyber-security data privacy standards.
Alanna Emrick, microbiology manager at UMC Health System, said: “BD understands our lab needs an advanced informatics solution that supports integrated workflow across lab instruments, with access to data across all systems to better utilise our resources, reduce turnaround times and error rates, and show efficiency data in order to maximise the usage of our instrumentation to ultimately allow us to better serve our physicians and patients.”
BD also unveiled two other new solutions at ECCMID – BD Cor and BD Kiestra ID/AST.
BD COR system is a new high-throughput molecular platform designed to support a menu of clinically differentiated assays for women’s health, sexually transmitted infections and gastrointestinal (GI) applications. The automated system integrates the pre-analytical and analytical steps needed to process samples and provide actionable results, while reducing hands on time for laboratory staff and reducing the potential for manual errors.
The company announced that BD Kiestra ID/AST modules will be new additions to the BD Kiestra solution that automate the processing steps for bacterial identification and antibiotic susceptibility testing using the BD Bruker MALDI and BD Phoenix systems. These unique laboratory automation solutions use a single organism to ensure that the same bacteria is used in both tests.
Dave Hickey, president, Diagnostic Systems at BD, said: “We aim to bring our customers the most comprehensive portfolio of high-quality diagnostic tools, because we understand that important medical decisions about patient management and treatment rely on our products. These innovative new solutions will enable more robust processing of clinical samples, and faster, more comprehensive reporting of results back to clinicians.”